Lab21 Healthcare is a global provider of state-of-the-art diagnostic products and services, supporting blood bank screening, medical diagnostics and drug discovery. Its customers include international healthcare providers, pharmaceutical and biotechnology companies.
The Diagnostic Product division of the Company manufactures immunodiagnostic kits and reagents that are distributed into 110 countries globally, and is focused on infectious diseases for the blood banking market. The company is the leading provider of syphilis tests to national blood supply services throughout Europe, and is also a major provided of malaria tests.
The Clinical Services division has a growing test portfolio providing companion diagnostics and high technology molecular assays for the growing integration of personalised medicine into healthcare. These services are currently in infectious diseases, oncology and pharmacogenetics areas with emerging interests in cardiovascular and metabolic disease.
Lab21's clinical reference laboratory and corporate office is based in Cambridge and has additional UK manufacturing sites in Newmarket, Bridport and Ipswich. It also has R&D operations in Cape Town, South Africa. The Company's investors include Merlin Biosciences, Nexus Medical Partners, Medicis Capital, Rowan Dartington and Kreos Capital.